Implementation of Pharmacogenomics (PGx) into Molecular Tumor Boards (PGxMTB) in Europe: Improved prediction of PGx phenotypes using germline and tumor multiomics data

Purpose and goal

PGxMTB aims to integrate germline and tumor pharmacogenomic data into Molecular Tumor Boards to improve cancer therapy selection, dosing and safety. By developing a comprehensive PGx and multiomics pipeline, validated across adult and pediatric cohorts, the project seeks to enhance precision oncology and reduce adverse drug reactions.

Expected effects and result

PGxMTB will deliver a validated PGx–multiomics pipeline, identify novel germline and somatic PGx markers, and establish liquid-biopsy–based liver PGx phenotyping. These outputs will improve MTB decision-making, optimize drug selection and dosing, reduce toxicity, and support cost-effective, more precise cancer therapy.

Planned approach and implementation

PGxMTB develops a PGx–multiomics pipeline, predicts functional effects of rare variants, validates findings in adult and pediatric cohorts, and measures liver PGx phenotypes via liquid biopsies. The project integrates PGx modules into MTBs, trains clinicians, engages patients, and evaluates health-economic impact.